{"id":11225,"date":"2025-03-29T16:55:27","date_gmt":"2025-03-29T23:55:27","guid":{"rendered":"https:\/\/citystuff.com\/los-angeles\/?p=11225"},"modified":"2025-03-29T16:55:27","modified_gmt":"2025-03-29T23:55:27","slug":"23andme-bankruptcy-puts-customer-genetic-data-at-risk","status":"publish","type":"post","link":"https:\/\/citystuff.com\/los-angeles\/23andme-bankruptcy-puts-customer-genetic-data-at-risk\/","title":{"rendered":"23andMe Bankruptcy Puts Customer Genetic Data at Risk"},"content":{"rendered":"

Introduction to 23andMe Bankruptcy and Genetic Data Concerns<\/h1>\n

When Christina Snyder Monahan of Irvine first received her genetic results from 23andMe three years ago, she thought there was a mistake. The DNA sample she had sent to the company revealed that she was nearly 50% Persian, though to her knowledge, she didn\u2019t have any Persian relatives. More than a year later, her mother admitted to having an \u201cencounter\u201d with another man, who was her actual biological father and not the man who raised her.<\/p>\n

What Happens to the DNA?<\/h2>\n

After adjusting to the shock, Monahan embraced the news, using 23andMe to meet relatives she never knew she had, including a first cousin and four half-siblings. Her biological father died before she learned of his existence. One of 15 million people who gave their genetic information to 23andMe, Monahan is now processing the news that the South San Francisco-based company filed for bankruptcy and is preparing to sell its trove of sensitive data. She values the connections the platform has brought her, she said, but is worried about where her genetic material could end up, echoing the concerns of other customers.<\/p>\n

\u201cThe attorney general of California is suggesting that people delete their accounts and that is making me think twice,\u201d Monahan said. \u201cThere might be danger lurking out there or repercussions.\u201d Once a promising company briefly valued at $6 billion after it went public in 2021, 23andMe popularized at-home DNA test kits and spawned a cottage industry of ancestry hunters and true crime sleuths. <\/p>\n

But the venture failed to attract repeat customers and has been unable to use the power of genome-mapping to expand into other revenue streams such as drug development. The company also fell victim to internal squabbles, all of which led to the chief executive\u2019s resignation and a Chapter 11 bankruptcy filing on Sunday. The U.S. Bankruptcy Court for the Eastern District of Missouri this week authorized 23andMe to sell substantially all of its assets, including its database of genetic information.<\/p>\n

Spit Parties and the Rise of 23andMe<\/h2>\n

Though any potential buyer must agree to comply with 23andMe\u2019s privacy policy, the uncertain future of the data has raised concerns about whether it could fall into the wrong hands. 23andMe began nearly two decades ago when co-founder Linda Avey had the idea for a direct-to-consumer genetic testing service. Anne Wojcicki met Avey through her then-boyfriend, Google co-founder Sergey Brin, who had expressed interest in Avey\u2019s work. The pair co-founded the company in 2006, and Wojcicki was named its CEO.<\/p>\n

A year later, Wojcicki and Brin married, and Google announced its investment in 23andMe shortly after. In 2009, wanting to run the company herself, Wojcicki persuaded two independent board members to fire Avey, according to the Wall Street Journal. Originally priced at $399, the DNA test kits attracted attention but were too expensive for the average consumer. That changed in 2012 when new investor funding allowed the company to reduce the price of the kits to $99 for ancestry services and $199 for health and ancestry information.<\/p>\n

Signs of Trouble<\/h2>\n

The kits soon became birthday gifts and stocking stuffers. At its peak, 23andMe attracted celebrity attention and held \u201cspit parties,\u201d where high-profile customers spit into a tube to provide their DNA sample. The samples helped people discover entirely new family trees and could reveal consequential health information, like a genetic predisposition to cancer. The genetic data collected by services similar to 23andMe was used to catch the infamous Golden State Killer in 2018. While the company\u2019s rise was celebrated, its expansion efforts were hobbled by challenges.<\/p>\n

In 2013, the Federal Drug Administration ordered a halt in sales of the test kits because 23andMe hadn\u2019t gotten the agency\u2019s approval to market the kits. The company later received approval after it completed a regulatory review process. Moreover, because users need to provide a DNA sample only once to take advantage of 23andMe\u2019s services, the company failed to establish a sustainable business model based on repeat customers. Additionally, 23andMe struggled to license its tech to pharmaceutical companies, which could have boosted profits.<\/p>\n

Concerns Over Data Privacy<\/h3>\n

Last November, the company announced it would lay off 40% of its workforce, or more than 200 employees, and shut down its therapeutics division. Company shares have plummeted in value, dropping more than 81% so far this year. The day after the bankruptcy announcement, shares fell roughly 50% and closed Friday at 61 cents. Jo Levy, a Northern California trial lawyer and 23andMe customer, said she used the platform to connect with relatives she had never met before. Despite the attorney general\u2019s warning, she urged consumers not to panic about the fate of their data.<\/p>\n

Potential Buyers and Data Security<\/h3>\n

\u201cThe fact that they filed for bankruptcy doesn\u2019t mean that tomorrow some nefarious company is going to purchase the data,\u201d Levy said. \u201cThere could be many reasons why people would want to maintain their accounts and I would caution people not to overreact.\u201d Wojcicki has made clear her intentions to bid on the company with a post on X last week. Her resignation came weeks after a company board committee rejected her acquisition proposal, and last September, all independent board members resigned after failed negotiations with Wojcicki.<\/p>\n

Conclusion<\/h2>\n

The potential sale of the company\u2019s genetic data is unprecedented, said Christo, the computer sciences professor. His fear is that a company will seek to purchase 23andMe solely to access and use its data. \u201cThere are certainly other databases full of genetic information, but they\u2019re held by researchers like hospitals and are subject to very different ethical guidelines than a private company,\u201d he said. \u201cI\u2019ve never heard of anything like this happening before.\u201d<\/p>\n

FAQs<\/h2>\n